Alcresta Therapeutics
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
130 Turner Street Building 3 Ste 200, Wa...Website
www.alcresta.comRevenue
$21.6 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Alcresta Therapeutics
Alcresta Therapeutics specializes in enzyme-based products aimed at improving enteral nutrition for patients suffering from fat malabsorption due to rare diseases. Their flagship product, RELiZORB, utilizes patented microbead/enzyme technology to enhance fat digestion and absorption for individuals on enteral feeding. The company primarily serves patients with serious medical conditions, including cystic fibrosis and pancreatitis, who require nutritional support. Alcresta is committed to advancing clinical research and improving health outcomes for these patients.Explore more
Alcresta Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Alcresta Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Alcresta Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Alcresta Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Alcresta Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Click to see if Alcresta Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Alcresta Therapeutics recently announced quarterly report
Check out if Alcresta Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Alcresta Therapeutics
Product Launch: Get notified when Alcresta Therapeutics launches new products
Recommended Actions
Reach out to Masked Content who joined Alcresta Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Alcresta Therapeutics
Compare insights from companies similar to Alcresta Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$21.9M
51-200
Private
-
1992
ML
Michael LyttonGroup Executive VP-Corp Development and Strategy and Gen Manager
Company Profile Activity
Activity Insights
Alcresta Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Alcresta Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Alcresta Therapeutics.
Alcresta Therapeutics financials insights
Gather financial insights about Alcresta Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2012
Series A
$10M
2013
Series B
$10M
2016
Private Equity
$50.9M
Series C
$49.4M
2017
Private Equity
$10M
Alcresta Therapeutics Tech Stack
A closer look at the technologies used by Alcresta Therapeutics
Most Recent Scoops
Project
Product Management, Intellectual Property, Medical Research, Pharmaceuticals
Mergers & Acquisitions (M&A)
Mergers & Acquisitions
Facilities Relocation / Expansion
Facilities Relocation/Expansion
Facilities Relocation / Expansion
Facilities Relocation/Expansion
Lateral Move
Executive Move
Executive Moves, Lateral Move
Alcresta Therapeutics News & Media
Alcresta Therapeutics Announces Publication of Real-World Evidence Showing Improvements in Growth for Children Ages 1 to 5 Years Old With Use of RELiZORB®
Clinical data published in Nutrients highlights significant improvements in weight and body mass index (BMI) z-scores with use of RELiZORB WALTHAM, Mass., Jan. 23, 2026 /PRNewswire/ -- Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and...Alcresta Therapeutics Announces FDA Clearance for Expanded Use of RELiZORB® (iMMOBILIZED LIPASE) Cartridge for Neonates and Infants
RELiZORB is now available for patients of all ages to hydrolyze fats during enteral feeding WALTHAM, Mass., Nov. 3, 2025 /PRNewswire/ -- Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, today announced...Alcresta Therapeutics Announces Enrollment of First Patient in Clinical Trial Evaluating Use of RELiZORB in Critical Care Patients at Inova Fairfax Medical Campus
WALTHAM, Mass., June 16, 2025 /PRNewswire/ -- Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, today announced that Inova Fairfax Medical Campus (Inova) has enrolled the first patient in an...Alcresta Therapeutics Announces Enrollment of First Patient in Clinical Trial Evaluating Use of RELiZORB in Pancreatitis Patients at Massachusetts General Hospital
WALTHAM, Mass., April 29, 2025 /PRNewswire/ -- Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, today announced that Massachusetts General Hospital (MGH) has enrolled the first patient in an...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Alcresta Therapeutics
Sign Up For FreeTo access detailed company insights
Alcresta Therapeutics specializes in enzyme-based products aimed at improving enteral nutrition for patients suffering from fat malabsorption due to rare diseases. Their flagship product, RELiZORB, utilizes patented microbead/enzyme technology to enhance fat digestion and absorption for individuals on enteral feeding. The company primarily serves p... Read More
